Sector

Healthcare und Life Sciences

 

The healthcare industry is one of the largest sectors of the German economy. Its innovative strength and employment intensity make it a clear growth driver. It can be divided into three major sub-sectors: medical care, the industrial healthcare sector and other sub-sectors. Around 5.8 million people are employed in the healthcare sector - this corresponds to almost 17% of the total labour force in Germany.

 

Date: June 2024     Type: Executive Summary

Current developments

A fragmented and crisis-proof market.

 

 

Health has become a ubiquitous megatrend, fuelled by Europe's ageing population and growing health awareness. The COVID-19 pandemic has considerably increased demand for healthcare products and led to a significant increase in private equity investment and investor interest, which has driven up the valuations of companies in the healthcare sector. The biotechnology sector in particular has benefited from this development, as it has been central to the development of new therapies and vaccines against the virus. This dynamic underlines the growing importance of innovation in biotechnology as a key component in the healthcare sector.

The shortage of skilled labour is proving to be a significant challenge in the healthcare and life sciences sector, but also offers opportunities for …

The shortage of skilled labour is proving to be a significant challenge in the healthcare and life sciences sector, but also offers opportunities for innovative companies. Particularly in the professional fields of medical and nursing care, where qualified specialists are in short supply, companies that invest in training and technology can benefit considerably. Low production costs in international comparison create competitive advantages, while the increasing legal regulations in the domestic market can encourage companies to set new standards through innovative solutions.

Company valuations in the healthcare and life sciences sector are influenced by a variety of factors, including the degree of innovation and research …

Company valuations in the healthcare and life sciences sector are influenced by a variety of factors, including the degree of innovation and research success, which are important for future revenues and market shares. Regulatory approvals by authorities such as the FDA or the EMA can also significantly increase the value, as can successful market access and market presence.

Financial performance and positive growth prospects play a major role, as do a strong intellectual property portfolio and effective patent protection. An experienced management team and the use of cutting-edge technologies such as AI to increase efficiency can also contribute to increasing value. In addition, the competitive position and market dynamics have a significant influence on valuations.

 

Companies with a strong focus on innovation and regular development of new products or therapies are particularly attractive to investors in the healt…

Companies with a strong focus on innovation and regular development of new products or therapies are particularly attractive to investors in the healthcare and life sciences sector. In addition, successful regulatory approvals and an extensive patent system increase their attractiveness by securing long-term competitive advantages. A sustainable business model, diversified income streams, a competent management team and clear competitive advantages, such as specialised knowledge or technological leadership, also increase the appeal. Last but not least, solid financial indicators, such as high profitability and steady sales growth, are decisive factors that make a company in this sector attractive to investors.

SXH Sektor Branche Healthcare

Wachstumsrate der letzten Jahre

 

 

+ 5,4 %

2021

+ 7,9 %

2022

- 1 %

2023

Trends

Artificial intelligence and machine learning

 

Artificial intelligence (AI) continues to revolutionise the healthcare industry by making diagnoses more accurate and treatments more efficient. The integration of AI into medical devices and systems enables faster analysis of medical data, which not only improves the quality of treatment but also reduces costs through optimised processes. In addition, the use of AI in research promotes the development of new drugs by accelerating clinical trials and improving predictive models for disease progression.

 

Privatisation and consolidation

 

The trend towards more private healthcare providers is continuing, with the number of hospitals tending to fall. This leads to the formation of larger healthcare providers, which strengthen their market position through economies of scale. This consolidation enables large providers to offer more comprehensive and specialised services, which contributes to an overall increase in efficiency in the healthcare system.

 

Future trends

 

Medical-technical progress is driving the development of innovative treatment methods, including new drugs and personalised therapy approaches. However, these advances are often accompanied by high costs and long authorisation procedures. In addition, the spectrum of diseases is changing, with an increase in chronic and mental illnesses. This development requires complex, long-term and cost-intensive therapeutic approaches. At the same time, the healthcare industry is a key driver of technological innovation, which is closely linked to the data processing and electronics industry and invests significantly in new technologies.

Transaktionen
Erfolgreiche Deals

Advisor to H+E Pharma GmbH

Saxenhammer exclusively advised H+E Pharma GmbH together with its subsidiary S-Tec GmbH on the sale to BW Water GmbH. As part of the transaction, the property could also be transferred to the buyer.

HE Pharma transparent logo
BW WATER logo

Advisor to CURATA Care Holding GmbH

curata logo
capital bay logo

Advisor to PIERVAL

Advising PIERVAL on the purchase of two accommodation facilities from Medicharme

PIERVAL Unternehmenskauf

Advisor to Hoshi International Inc.

Advisor to Hoshi International Inc. on its CAD $18.5 million Series A financing round

Hoshi International Fundraise
Flora Growth Corp Fundraise

Advisor to Clínica AMO

Advising Clínica AMO on the sale to Diagnosticos da America SA

Clinica AMO Unternehmensverkauf
Diagnosticos da America SA Unternehmensverkauf

Advisor to Australian Botanical Products

Advisor to Australian Botanical Products on the acquisition of Ixom

Australian Botanical Products Unternehmenskauf
Ixom Unternehmenskauf

Advising the German life science company DYPHOX

Advising German life science company DYPHOX on its €2.5 million capital increase

DYPHOX Kapitalerhoehung
Private Investor Kapitalerhoehung

Consultation of Teccom Pharma GmbH

Advising Teccom Pharma GmbH on the sale to a private investor

Teccom Pharma GmbH Unternehmensverkauf
Private Investor Sondersituationen

Advisor to IRW Consulting

Advising IRW Consulting on the sale to LINK Medical Research

IRW Consulting Unternehmensverkauf
LINK Medical Research Unternehmensverkauf

Advisor to Curasan AG

Advising Curasan AG on the sale to Donau Invest

Curasan AG Sondersituationen
Donau Invest Sondersituationen

Advisor to Medcom Inc.

Advising Medcom Inc. on the sale to Elfa

Medcom Inc Unternehmensverkauf
Elfa Unternehmensverkauf

Advisor to Fagron NV

Advising Fagron NV on the sale to HL-Technology GmbH

Fagron NV Unternehmensverkauf
HL Technology GmbH Unternehmensverkauf

Advisor to Lykon GmbH

Advisor to Lykon GmbH on the sale to a private investor

Lykon GmbH Sondersituationen
Private Investor Sondersituationen

Advisor to Organic Formulations

Advising Organic Formulations on the sale to Martin & Pleasance

Organic Formulations Unternehmensverkauf
Martin and Pleasance Unternehmensverkauf

Beratung der Dr.Hato

Beratung der Dr.Hato bei der Veräußerung an Mars Petcare

DrHato Unternehmensverkauf
Mars Petcare Unternehmensverkauf

Advisor to Telemis

Advisor to Telemis on the acquisition of itz-medicom GmbH

Telemis Unternehmenskauf
itz medicom GmbH Unternehmenskauf

Advisor to Soft Intelligent Therapeutics Biotech

Advising Soft Intelligent Therapeutics Biotech in management buyout

Soft Intelligent Therapeutics Biotech Sondersituationen
Management Sondersituationen

Advisor to Heliocentris Gruppe

Advisor to the Heliocentris Group on the sale to ODASCO LLC

Heliocentris Gruppe Sondersituationen
ODASCO LLC Sondersituationen

Advisor to DotNext

Advising DotNext on the sale to Evolucare

DotNext Unternehmensverkauf
Evolucare Unternehmensverkauf

Advisor to Bianalisi

Advising Bianalisi on the acquisition of Centro Medico Rovigo, Centro Attivití Motorie, Centro Medico Polesano, Istituto Sherman, Servizi Aziendali Rovigo

Bianalisi Unternehmenskauf
Centro Medico Rovigo Centro Attiviti Motorie Centro Medico Polesano Istituto Sherman Servizi Aziendali Rovigo Unternehmenskauf

Advisor to Fairform GmbH

Advisor to Fairform GmbH on the sale to Gebrueder Sakman Winterdienst Berlin Betriebs GmbH & Co. KG

Fairform GmbH Sondersituationen
Gebrueder Sakman Winterdienst Berlin Betriebs GmbH and Co KG Sondersituationen

Consultation of Haus Cordula e.V.

Advising Haus Cordula e.V. on the sale to the Azurit Group

Cordula eV Sondersituationen
Azurit Gruppe Sondersituationen

Advisor to CompuGroup Medical AG

Advisor to CompuGroup Medical AG on the acquisition of Windoc

CompuGroup Medical AG Unternehmenskauf
Windoc Unternehmenskauf

Advisor to GE Medical

Advising GE Medical on the acquisition of Instrumentarium Oyj

GE Medical Unternehmenskauf
Instrumentarium Oyj Unternehmenskauf

Expert opinion

Prospects for success in the sector

 

Healthcare & Life Sciences is a clear growth market. An ageing population, particularly in the western world, and increased health awareness among the younger generation are the main drivers here. In addition, technological progress, particularly in biotech, is enabling the development of new drugs and therapies.

There is a trend towards size, which is leading to a consolidation of the fragmented market.

SXH unternehmensverkauf beratung unternehmenswert

The healthcare industry is a key driver of innovation and is closely linked to new technologies that continue to drive medical-technical progress, including new drugs and personalised therapy approaches.

Dr. Nicholas Hanser
Partner | Head of Technology

Your contact partners

 

Saxenhammer has in-depth specialist and industry knowledge and can draw on a broad network of industry experts with many years of transaction experience.

 

We will be happy to advise you!


Dr. Nicholas Hanser
Partner | Head of Technology


Matthias Grau
Partner